









Markets
/
Stocks
/
nasdaq-inmb
/

INmune Bio Inc

INMB

1.770USD

+0.050+2.91%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

47.06MMarket Cap

LossP/E TTM



INmune Bio Inc

1.770

+0.050+2.91%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of INmune Bio Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

INmune Bio Inc's Score

Industry at a Glance

Industry Ranking

143 / 407

Overall Ranking

278 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

8.400

Target Price

+388.37%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

INmune Bio Inc Highlights

StrengthsRisks

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03) Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The NK Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic and solid tumor malignancies, and chronic inflammation.

Growing

The company is in a growing phase, with the latest annual income totaling USD 14.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 14.00K.

Overvalued

The company’s latest PE is -0.85, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.75M shares, decreasing 17.56% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 1.27K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 1.74.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 7.58, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.58

Change



Financials

9.84

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.59

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.85

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.60

Key Metrics

Free cash flow

No Data

INmune Bio Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 8.16, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.85, which is -18.34% below the recent high of -0.69 and -886.93% above the recent low of -8.39.

Score

Industry at a Glance

Previous score

8.16

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 143/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 7.00, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for INmune Bio Inc is 7.00, with a high of 21.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Buy

Current Rating

8.400

Target Price

+388.37%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

INmune Bio Inc

INMB

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 4.97, which is lower than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 1.98 and the support level at 1.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.95

Change

0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.001

Sell

RSI(14)

42.763

Neutral

STOCH(KDJ)(9,3,3)

24.308

Neutral

ATR(14)

0.100

High Vlolatility

CCI(14)

-126.369

Sell

Williams %R

69.231

Sell

TRIX(12,20)

-0.460

Sell

StochRSI(14)

71.650

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.770

Sell

MA10

1.802

Sell

MA20

1.839

Sell

MA50

1.927

Sell

MA100

2.583

Sell

MA200

5.283

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 21.62%, representing a quarter-over-quarter decrease of 58.67%. The largest institutional shareholder is The Vanguard, holding a total of 847.75K shares, representing 3.19% of shares outstanding, with 3.75% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Tesi (Raymond Joseph)

1.55M

Lowdell (Mark William)

1.51M

Moss (David J.)

1.29M

BlackRock Institutional Trust Company, N.A.

1.05M

+19.52%

The Vanguard Group, Inc.

Star Investors

847.75K

+2.56%

UBS Financial Services, Inc.

437.39K

+218.53%

Geode Capital Management, L.L.C.

389.93K

+6.87%

Raymond James Financial Services Advisors, Inc.

316.94K

-16.37%

State Street Investment Management (US)

275.39K

+16.63%

Dauntless Investment Group, LLC

248.54K

+90.19%

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 2.25, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.92. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.